[{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ridgeline Therapeutics Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"IL-2 conjugates","moa":"CD25 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ajinomoto Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Immunocytokines","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Ajinomoto","highestDevelopmentStatusID":"1","companyTruncated":"Bright Peak Therapeutics \/ Ajinomoto"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"BPT-143","moa":"IL-2 receptor alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ RA Capital","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ RA Capital"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"LZM009","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bright Peak Therapeutics \/ Bright Peak Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Bright Peak Therapeutics \/ Bright Peak Therapeutics"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BPT-143","moa":"IL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Series C Financing","leadProduct":"BPT567","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"BPT567","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Bright Peak Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : BPT567, is a bifunctional PD1-IL18 immunoconjugate aimed at activating and enhancing immune responses directly within the tumor microenvironment.

Product Name : BPT567

Product Type : Large molecule

Upfront Cash : Not Applicable

October 17, 2024

Lead Product(s) : BPT567

Therapeutic Area : Oncology

Highest Development Status : Phase I/ Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : The proceeds from the Series C financing will be used to advance the Bright Peak Therapeutics lead product BPT567 into a clinical trial for the treatment of neoplasms.

Product Name : BPT567

Product Type : Large molecule

Upfront Cash : Undisclosed

June 11, 2024

Lead Product(s) : BPT567

Therapeutic Area : Oncology

Highest Development Status : IND Enabling

Sponsor : Johnson & Johnson

Deal Size : $90.0 million

Deal Type : Series C Financing

blank

03

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : BPT-143, full-length, folded and PEGylated protein demonstrated power of protein synthesis platform to engineer pleiotropic native cytokines into optimized therapeutics and exploiting technology to develop pipeline of novel designer cytokines and multi-m...

Product Name : BPT-143

Product Type : Large molecule

Upfront Cash : Not Applicable

April 04, 2022

Lead Product(s) : BPT-143

Therapeutic Area : Oncology

Highest Development Status : IND Enabling

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : Under the terms of the license agreement, Bright Peak will receive the right to develop, manufacture and commercialize PD-1 ICs, including LZM009 on a worldwide basis while Livzon retains certain rights of first negotiation to obtain exclusivity in the g...

Product Name : LZM009

Product Type : Large molecule

Upfront Cash : Undisclosed

November 16, 2021

Lead Product(s) : LZM009

Therapeutic Area : Oncology

Highest Development Status : Phase I

Recipient : Livzon Pharmaceutical Group

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

05

PharmScience R&D
Not Confirmed
PharmScience R&D
Not Confirmed

Details : BPT-143 is an enhanced, half-life extended, IL-2 cytokine that uses small modifications to amino acid side chains to block binding to IL-2 receptor alpha, and enhance binding to IL-2 receptor beta.

Product Name : BPT-143

Product Type : Large molecule

Upfront Cash : Undisclosed

June 10, 2021

Lead Product(s) : BPT-143

Therapeutic Area : Oncology

Highest Development Status : IND Enabling

Sponsor : RA Capital

Deal Size : $107.0 million

Deal Type : Series B Financing

blank

06

BioAsia
Not Confirmed
BioAsia
Not Confirmed

Details : As part of the collaboration and license agreement with Ajinomoto Co., the AJICAP® technology will be used to conjugate Bright Peak’s enhanced cytokines as payloads to certain antibodies, creating novel and proprietary Bright Peak Immunocytokines.

Product Name : Undisclosed

Product Type : Large molecule

Upfront Cash : Undisclosed

March 25, 2021

Lead Product(s) : Immunocytokines

Therapeutic Area : Oncology

Highest Development Status : Undisclosed

Sponsor : Ajinomoto Bio-Pharma

Deal Size : Undisclosed

Deal Type : Collaboration

blank

07

BioAsia
Not Confirmed
BioAsia
Not Confirmed

Details : Bright Peak’s technology platform allows a wide range of proteins to be chemically assembled de novo. The company has validated the platform by creating a portfolio of designer cytokines with the potential to be advanced as novel immune-oncology therap...

Product Name : Undisclosed

Product Type : Large molecule

Upfront Cash : Undisclosed

July 28, 2020

Lead Product(s) : IL-2 conjugates

Therapeutic Area : Oncology

Highest Development Status : IND Enabling

Sponsor : Ridgeline Therapeutics Discovery

Deal Size : $35.0 million

Deal Type : Series A Financing

blank